Treating breast cancer using estrogen receptor (ER) antagonists is the most established molecular targeted therapy approach as compared to other receptors (Sharma et al., 2018; Damodaran and Hortobagyi, 2021). The gene discussed is ESR1; the disease is breast carcinoma.